Healthcare’s Q3 2025 boom: Robotics and weight-loss drugs lead the charge
The healthcare sector witnessed notable shifts in the third quarter of 2025, with major players reporting strong growth in key areas. Surgical robotics and weight-loss drugs dominated headlines, as companies expanded their market presence and revenue streams. Several firms also reinforced their financial stability through long-term dividend strategies.
Intuitive Surgical continued its expansion in robotic-assisted surgery. The company’s installed base of surgical robots grew by 13% in Q3 2025. Procedures performed with its systems rose by 20% in the same period. A significant portion of its revenue comes from recurring parts and services, creating a steady income stream.
The third quarter highlighted the growing importance of robotics in surgery and the dominance of weight-loss drugs in pharmaceutical sales. Companies like Intuitive Surgical and Medtronic are capitalising on technological advancements, while firms like Eli Lilly and Pfizer strengthen their positions in high-demand drug markets. Dividend consistency from Johnson & Johnson and Novartis further reinforces their appeal to conservative investors.
